ID   PCSK9_HUMAN             Reviewed;         692 AA.
AC   Q8NBP7; A8T640; C0JYY9; Q5PSM5; Q5SZQ2;
DT   07-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 3.
DT   22-JUL-2015, entry version 144.
DE   RecName: Full=Proprotein convertase subtilisin/kexin type 9;
DE            EC=3.4.21.-;
DE   AltName: Full=Neural apoptosis-regulated convertase 1;
DE            Short=NARC-1;
DE   AltName: Full=Proprotein convertase 9;
DE            Short=PC9;
DE   AltName: Full=Subtilisin/kexin-like protease PC9;
DE   Flags: Precursor;
GN   Name=PCSK9; Synonyms=NARC1; ORFNames=PSEC0052;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ILE-474 AND
RP   GLU-670.
RA   Chiang L.W.;
RT   "Nucleic acid molecules derived from rat brain and programmed cell
RT   death models.";
RL   Patent number WO0131007, 03-MAY-2001.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ILE-474 AND
RP   GLU-670.
RX   PubMed=17971861; DOI=10.1371/journal.pone.0001098;
RA   Ding K., McDonough S.J., Kullo I.J.;
RT   "Evidence for positive selection in the C-terminal domain of the
RT   cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14
RT   primate species.";
RL   PLoS ONE 2:E1098-E1098(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ILE-474.
RC   TISSUE=Cerebellum, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-23 INS; LEU-46;
RP   VAL-53; SER-425; THR-443; ILE-474; ARG-553; PRO-619 AND GLU-670.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-23 INS; ILE-474
RP   AND GLU-670.
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS ILE-474
RP   AND GLU-670.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   PROTEIN SEQUENCE OF N-TERMINUS, CHARACTERIZATION, AND MUTAGENESIS OF
RP   CYS-67; HIS-226 AND ASN-533.
RX   PubMed=12552133; DOI=10.1073/pnas.0335507100;
RA   Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B.,
RA   Stifani S., Basak A., Prat A., Chretien M.;
RT   "The secretory proprotein convertase neural apoptosis-regulated
RT   convertase 1 (NARC-1): liver regeneration and neuronal
RT   differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:928-933(2003).
RN   [9]
RP   AUTOCATALYTIC CLEAVAGE SITE.
RX   PubMed=14622975; DOI=10.1016/j.abb.2003.09.011;
RA   Naureckiene S., Ma L., Sreekumar K., Purandare U., Lo C.F., Huang Y.,
RA   Chiang L.W., Grenier J.M., Ozenberger B.A., Jacobsen J.S.,
RA   Kennedy J.D., DiStefano P.S., Wood A., Bingham B.;
RT   "Functional characterization of Narc 1, a novel proteinase related to
RT   proteinase K.";
RL   Arch. Biochem. Biophys. 420:55-67(2003).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   GLYCOSYLATION AT ASN-533, SULFATION AT TYR-38, AND CLEAVAGE AT ARG-218
RP   BY FURIN AND PCSK5.
RX   PubMed=16912035; DOI=10.1074/jbc.M606495200;
RA   Benjannet S., Rhainds D., Hamelin J., Nassoury N., Seidah N.G.;
RT   "The proprotein convertase (PC) PCSK9 is inactivated by furin and/or
RT   PC5/6A: functional consequences of natural mutations and post-
RT   translational modifications.";
RL   J. Biol. Chem. 281:30561-30572(2006).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH LDLR.
RX   PubMed=17461796; DOI=10.1111/j.1600-0854.2007.00562.x;
RA   Nassoury N., Blasiole D.A., Tebon Oler A., Benjannet S., Hamelin J.,
RA   Poupon V., McPherson P.S., Attie A.D., Prat A., Seidah N.G.;
RT   "The cellular trafficking of the secretory proprotein convertase PCSK9
RT   and its dependence on the LDLR.";
RL   Traffic 8:718-732(2007).
RN   [13]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=18197702; DOI=10.1021/bi7016359;
RA   Fan D., Yancey P.G., Qiu S., Ding L., Weeber E.J., Linton M.F.,
RA   Fazio S.;
RT   "Self-association of human PCSK9 correlates with its LDLR-degrading
RT   activity.";
RL   Biochemistry 47:1631-1639(2008).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH BACE1.
RX   PubMed=18660751; DOI=10.1038/embor.2008.132;
RA   Jonas M.C., Costantini C., Puglielli L.;
RT   "PCSK9 is required for the disposal of non-acetylated intermediates of
RT   the nascent membrane protein BACE1.";
RL   EMBO Rep. 9:916-922(2008).
RN   [15]
RP   PHOSPHORYLATION AT SER-47 AND SER-688, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=18498363; DOI=10.1111/j.1742-4658.2008.06495.x;
RA   Dewpura T., Raymond A., Hamelin J., Seidah N.G., Mbikay M.,
RA   Chretien M., Mayne J.;
RT   "PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo
RT   and circulates as a phosphoprotein in humans.";
RL   FEBS J. 275:3480-3493(2008).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH VLDLR AND
RP   LRP8/APOER2.
RX   PubMed=18039658; DOI=10.1074/jbc.M708098200;
RA   Poirier S., Mayer G., Benjannet S., Bergeron E., Marcinkiewicz J.,
RA   Nassoury N., Mayer H., Nimpf J., Prat A., Seidah N.G.;
RT   "The proprotein convertase PCSK9 induces the degradation of low
RT   density lipoprotein receptor (LDLR) and its closest family members
RT   VLDLR and ApoER2.";
RL   J. Biol. Chem. 283:2363-2372(2008).
RN   [17]
RP   FUNCTION, INTERACTION WITH ANXA2, VARIANT HCHOLA3 TYR-374,
RP   CHARACTERIZATION OF VARIANT HCHOLA3 TYR-374, VARIANT GLU-554, AND
RP   CHARACTERIZATION OF VARIANT GLU-554.
RX   PubMed=18799458; DOI=10.1074/jbc.M805971200;
RA   Mayer G., Poirier S., Seidah N.G.;
RT   "Annexin A2 is a C-terminal PCSK9-binding protein that regulates
RT   endogenous low density lipoprotein receptor levels.";
RL   J. Biol. Chem. 283:31791-31801(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   FUNCTION.
RX   PubMed=22074827; DOI=10.1016/j.bbrc.2011.10.110;
RA   Chen Y., Wang H., Yu L., Yu X., Qian Y.W., Cao G., Wang J.;
RT   "Role of ubiquitination in PCSK9-mediated low-density lipoprotein
RT   receptor degradation.";
RL   Biochem. Biophys. Res. Commun. 415:515-518(2011).
RN   [21]
RP   INTERACTION WITH LDLR.
RX   PubMed=21149300; DOI=10.1074/jbc.M110.199042;
RA   Yamamoto T., Lu C., Ryan R.O.;
RT   "A two-step binding model of PCSK9 interaction with the low density
RT   lipoprotein receptor.";
RL   J. Biol. Chem. 286:5464-5470(2011).
RN   [22]
RP   DOMAIN C-TERMINAL.
RX   PubMed=22027821; DOI=10.1074/jbc.M111.273474;
RA   Du F., Hui Y., Zhang M., Linton M.F., Fazio S., Fan D.;
RT   "Novel domain interaction regulates secretion of proprotein convertase
RT   subtilisin/kexin type 9 (PCSK9) protein.";
RL   J. Biol. Chem. 286:43054-43061(2011).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [24]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH APOB.
RX   PubMed=22580899; DOI=10.1161/ATVBAHA.112.250043;
RA   Sun H., Samarghandi A., Zhang N., Yao Z., Xiong M., Teng B.B.;
RT   "Proprotein convertase subtilisin/kexin type 9 interacts with
RT   apolipoprotein B and prevents its intracellular degradation,
RT   irrespective of the low-density lipoprotein receptor.";
RL   Arterioscler. Thromb. Vasc. Biol. 32:1585-1595(2012).
RN   [25]
RP   REVIEW.
RX   PubMed=18280815; DOI=10.1016/j.bbalip.2008.01.003;
RA   Lopez D.;
RT   "PCSK9: an enigmatic protease.";
RL   Biochim. Biophys. Acta 1781:184-191(2008).
RN   [26]
RP   REVIEW.
RX   PubMed=18649882; DOI=10.1016/j.atherosclerosis.2008.06.010;
RA   Lambert G., Charlton F., Rye K.A., Piper D.E.;
RT   "Molecular basis of PCSK9 function.";
RL   Atherosclerosis 203:1-7(2009).
RN   [27]
RP   REVIEW.
RX   PubMed=19930098; DOI=10.1111/j.1365-2796.2009.02167.x;
RA   Mousavi S.A., Berge K.E., Leren T.P.;
RT   "The unique role of proprotein convertase subtilisin/kexin 9 in
RT   cholesterol homeostasis.";
RL   J. Intern. Med. 266:507-519(2009).
RN   [28]
RP   REVIEW.
RX   PubMed=19020338; DOI=10.1194/jlr.R800091-JLR200;
RA   Horton J.D., Cohen J.C., Hobbs H.H.;
RT   "PCSK9: a convertase that coordinates LDL catabolism.";
RL   J. Lipid Res. 50:S172-S177(2009).
RN   [29]
RP   REVIEW.
RX   PubMed=21943799; DOI=10.1016/j.numecd.2011.06.002;
RA   Tibolla G., Norata G.D., Artali R., Meneghetti F., Catapano A.L.;
RT   "Proprotein convertase subtilisin/kexin type 9 (PCSK9): from
RT   structure-function relation to therapeutic inhibition.";
RL   Nutr. Metab. Cardiovasc. Dis. 21:835-843(2011).
RN   [30]
RP   REVIEW ON VARIANTS.
RX   PubMed=19191301; DOI=10.1002/humu.20882;
RA   Abifadel M., Rabes J.P., Devillers M., Munnich A., Erlich D.,
RA   Junien C., Varret M., Boileau C.;
RT   "Mutations and polymorphisms in the proprotein convertase subtilisin
RT   kexin 9 (PCSK9) gene in cholesterol metabolism and disease.";
RL   Hum. Mutat. 30:520-529(2009).
RN   [31]
RP   INVOLVEMENT IN LDLCQ1, AND VARIANT SER-174.
RX   PubMed=22417841; DOI=10.1016/j.atherosclerosis.2012.02.018;
RA   Slimani A., Jelassi A., Jguirim I., Najah M., Rebhi L., Omezzine A.,
RA   Maatouk F., Hamda K.B., Kacem M., Rabes J.P., Abifadel M., Boileau C.,
RA   Rouis M., Slimane M.N., Varret M.;
RT   "Effect of mutations in LDLR and PCSK9 genes on phenotypic variability
RT   in Tunisian familial hypercholesterolemia patients.";
RL   Atherosclerosis 222:158-166(2012).
RN   [32]
RP   FUNCTION, AND INTERACTION WITH SCNN1A; SCNN1B AND SCNN1G.
RX   PubMed=22493497; DOI=10.1074/jbc.M112.363382;
RA   Sharotri V., Collier D.M., Olson D.R., Zhou R., Snyder P.M.;
RT   "Regulation of epithelial sodium channel trafficking by proprotein
RT   convertase subtilisin/kexin type 9 (PCSK9).";
RL   J. Biol. Chem. 287:19266-19274(2012).
RN   [33]
RP   FUNCTION, INTERACTION WITH ANXA2, VARIANT GLN-482, CHARACTERIZATION OF
RP   VARIANT GLN-482, VARIANTS HCHOLA3 SER-218 AND TYR-374,
RP   CHARACTERIZATION OF VARIANTS HCHOLA3 SER-218 AND TYR-374, SULFATION,
RP   PHOSPHORYLATION, GLYCOSYLATION, AND SUBUNIT.
RX   PubMed=24808179; DOI=10.1074/jbc.M113.541094;
RA   Ly K., Saavedra Y.G., Canuel M., Routhier S., Desjardins R.,
RA   Hamelin J., Mayne J., Lazure C., Seidah N.G., Day R.;
RT   "Annexin A2 reduces PCSK9 protein levels via a translational mechanism
RT   and interacts with the M1 and M2 domains of PCSK9.";
RL   J. Biol. Chem. 289:17732-17746(2014).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 31-692.
RX   PubMed=17502100; DOI=10.1016/j.str.2007.04.004;
RA   Piper D.E., Jackson S., Liu Q., Romanow W.G., Shetterly S.,
RA   Thibault S.T., Shan B., Walker N.P.;
RT   "The crystal structure of PCSK9: a regulator of plasma LDL-
RT   cholesterol.";
RL   Structure 15:545-552(2007).
RN   [35]
RP   VARIANTS HCHOLA3 ARG-127 AND LEU-216, AND VARIANTS LEU-46; VAL-53 AND
RP   GLU-670.
RX   PubMed=12730697; DOI=10.1038/ng1161;
RA   Abifadel M., Varret M., Rabes J.-P., Allard D., Ouguerram K.,
RA   Devillers M., Cruaud C., Benjannet S., Wickham L., Erlich D.,
RA   Derre A., Villeger L., Farnier M., Beucler I., Bruckert E.,
RA   Chambaz J., Chanu B., Lecerf J.-M., Luc G., Moulin P., Weissenbach J.,
RA   Prat A., Krempf M., Junien C., Seidah N.G., Boileau C.;
RT   "Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.";
RL   Nat. Genet. 34:154-156(2003).
RN   [36]
RP   VARIANTS LEU-46; VAL-53; LYS-57; TRP-237; PHE-253; ASN-391; GLN-417;
RP   SER-425; THR-443; TRP-469; ILE-474; GLY-482; LEU-515; ARG-553;
RP   GLU-554; PRO-619 AND GLU-670.
RX   PubMed=16465619; DOI=10.1086/500615;
RA   Kotowski I.K., Pertsemlidis A., Luke A., Cooper R.S., Vega G.L.,
RA   Cohen J.C., Hobbs H.H.;
RT   "A spectrum of PCSK9 alleles contributes to plasma levels of low-
RT   density lipoprotein cholesterol.";
RL   Am. J. Hum. Genet. 78:410-422(2006).
RN   [37]
RP   INVOLVEMENT IN LDLCQ1, VARIANT LEU-23 INS, AND IMPACT ON FAMILIAL
RP   HYPERCHOLESTEROLEMIA.
RX   PubMed=19319977; DOI=10.1002/humu.21002;
RA   Abifadel M., Rabes J.-P., Jambart S., Halaby G., Gannage-Yared M.-H.,
RA   Sarkis A., Beaino G., Varret M., Salem N., Corbani S., Aydenian H.,
RA   Junien C., Munnich A., Boileau C.;
RT   "The molecular basis of familial hypercholesterolemia in Lebanon:
RT   spectrum of LDLR mutations and role of PCSK9 as a modifier gene.";
RL   Hum. Mutat. 30:E682-E691(2009).
RN   [38]
RP   INVOLVEMENT IN LDLCQ1, AND VARIANTS LEU-23 INS; LEU-46; VAL-53;
RP   SER-394; ILE-474 AND GLU-670.
RX   PubMed=22095935; DOI=10.1002/humu.21660;
RA   Huijgen R., Sjouke B., Vis K., de Randamie J.S., Defesche J.C.,
RA   Kastelein J.J., Hovingh G.K., Fouchier S.W.;
RT   "Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of
RT   pathogenic autosomal dominant hypercholesterolemic mutations with
RT   unexpected low LDL-Cl Levels.";
RL   Hum. Mutat. 33:448-455(2012).
CC   -!- FUNCTION: Crucial player in the regulation of plasma cholesterol
CC       homeostasis. Binds to low-density lipid receptor family members:
CC       low density lipoprotein receptor (LDLR), very low density
CC       lipoprotein receptor (VLDLR), apolipoprotein E receptor
CC       (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and
CC       promotes their degradation in intracellular acidic compartments
CC       (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance
CC       the degradation of the hepatic LDLR through a clathrin
CC       LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR
CC       from endosomes to the cell surface or direct it to lysosomes for
CC       degradation. Can induce ubiquitination of LDLR leading to its
CC       subsequent degradation (PubMed:18799458, PubMed:17461796,
CC       PubMed:18197702, PubMed:22074827). Inhibits intracellular
CC       degradation of APOB via the autophagosome/lysosome pathway in a
CC       LDLR-independent manner. Involved in the disposal of non-
CC       acetylated intermediates of BACE1 in the early secretory pathway
CC       (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-
CC       mediated Na(+) absorption by reducing ENaC surface expression
CC       primarily by increasing its proteasomal degradation. Regulates
CC       neuronal apoptosis via modulation of LRP8/APOER2 levels and
CC       related anti-apoptotic signaling pathways.
CC       {ECO:0000269|PubMed:17461796, ECO:0000269|PubMed:18039658,
CC       ECO:0000269|PubMed:18197702, ECO:0000269|PubMed:18660751,
CC       ECO:0000269|PubMed:18799458, ECO:0000269|PubMed:22074827,
CC       ECO:0000269|PubMed:22493497, ECO:0000269|PubMed:22580899}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000305};
CC   -!- ENZYME REGULATION: Its proteolytic activity is autoinhibited by
CC       the non-covalent binding of the propeptide to the catalytic
CC       domain. Inhibited by EGTA.
CC   -!- SUBUNIT: Monomer. Can self-associate to form dimers and higher
CC       multimers which may have increased LDLR degrading activity. The
CC       precursor protein but not the mature protein may form multimers.
CC       Interacts with APOB, VLDLR, LRP8/APOER2 and BACE1. The full length
CC       immature form (pro-PCSK9) interacts with SCNN1A, SCNN1B and
CC       SCNN1G. The pro-PCSK9 form (via C-terminal domain) interacts with
CC       LDLR. Interacts (via the C-terminal domain) with ANXA2 (via repeat
CC       Annexin 1); the interaction inhibits the degradation of LDLR
CC       (PubMed:18799458). {ECO:0000269|PubMed:17461796,
CC       ECO:0000269|PubMed:18039658, ECO:0000269|PubMed:18197702,
CC       ECO:0000269|PubMed:18660751, ECO:0000269|PubMed:18799458,
CC       ECO:0000269|PubMed:21149300, ECO:0000269|PubMed:22493497,
CC       ECO:0000269|PubMed:22580899, ECO:0000269|PubMed:24808179}.
CC   -!- INTERACTION:
CC       P07355:ANXA2; NbExp=7; IntAct=EBI-7539251, EBI-352622;
CC       P01130:LDLR; NbExp=10; IntAct=EBI-7539251, EBI-988319;
CC       P08253:MMP2; NbExp=4; IntAct=EBI-7539251, EBI-1033518;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Secreted. Endosome. Lysosome.
CC       Cell surface. Endoplasmic reticulum. Golgi apparatus.
CC       Note=Autocatalytic cleavage is required to transport it from the
CC       endoplasmic reticulum to the Golgi apparatus and for the secretion
CC       of the mature protein. Localizes to the endoplasmic reticulum in
CC       the absence of LDLR and colocalizes to the cell surface and to the
CC       endosomes/lysosomes in the presence of LDLR. The sorting to the
CC       cell surface and endosomes is required in order to fully promote
CC       LDLR degradation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8NBP7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8NBP7-2; Sequence=VSP_008844, VSP_008845, VSP_008846;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in neuro-epithelioma, colon
CC       carcinoma, hepatic and pancreatic cell lines, and in Schwann
CC       cells.
CC   -!- DOMAIN: The C-terminal domain (CRD) is essential for the LDLR-
CC       binding and degrading activities. {ECO:0000269|PubMed:22027821}.
CC   -!- DOMAIN: The catalytic domain is responsible for mediating its
CC       self-association. {ECO:0000269|PubMed:22027821}.
CC   -!- PTM: Cleavage by furin and PCSK5 generates a truncated inactive
CC       protein that is unable to induce LDLR degradation.
CC   -!- PTM: Undergoes autocatalytic cleavage in the endoplasmic reticulum
CC       to release the propeptide from the N-terminus and the cleavage of
CC       the propeptide is strictly required for its maturation and
CC       activation. The cleaved propeptide however remains associated with
CC       the catalytic domain through non-covalent interactions, preventing
CC       potential substrates from accessing its active site. As a result,
CC       it is secreted from cells as a propeptide-containing,
CC       enzymatically inactive protein. {ECO:0000269|PubMed:16912035}.
CC   -!- PTM: Phosphorylation protects the propeptide against proteolysis.
CC       {ECO:0000269|PubMed:18498363}.
CC   -!- POLYMORPHISM: Variant Leu-23 ins polymorphism in PCSK9 might have
CC       a modifier effect on LDLR mutation and familial
CC       hypercholesterolemia.
CC   -!- POLYMORPHISM: Genetic variations in PCSK9 define the low density
CC       lipoprotein cholesterol level quantitative trait locus 1 (LDLCQ1)
CC       [MIM:603776].
CC   -!- DISEASE: Hypercholesterolemia, autosomal dominant, 3 (HCHOLA3)
CC       [MIM:603776]: A familial condition characterized by elevated
CC       circulating cholesterol contained in either low-density
CC       lipoproteins alone or also in very-low-density lipoproteins.
CC       {ECO:0000269|PubMed:12730697}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the peptidase S8 family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 peptidase S8 domain. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC11572.1; Type=Frameshift; Positions=494; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/pcsk9/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AX127530; CAC38896.1; -; mRNA.
DR   EMBL; EF692496; ABV59216.1; -; mRNA.
DR   EMBL; AK075365; BAC11572.1; ALT_FRAME; mRNA.
DR   EMBL; AK124635; BAC85910.1; -; mRNA.
DR   EMBL; AY829011; AAV67948.1; -; Genomic_DNA.
DR   EMBL; FJ525880; ACN81318.1; -; Genomic_DNA.
DR   EMBL; AL589790; CAI17845.1; -; Genomic_DNA.
DR   EMBL; AC091609; CAI17845.1; JOINED; Genomic_DNA.
DR   EMBL; CH471059; EAX06660.1; -; Genomic_DNA.
DR   CCDS; CCDS603.1; -. [Q8NBP7-1]
DR   RefSeq; NP_777596.2; NM_174936.3. [Q8NBP7-1]
DR   UniGene; Hs.18844; -.
DR   PDB; 2P4E; X-ray; 1.98 A; A/P=1-692.
DR   PDB; 2PMW; X-ray; 2.30 A; A=31-152, B=153-692.
DR   PDB; 2QTW; X-ray; 1.90 A; A=29-152, B=153-692.
DR   PDB; 2W2M; X-ray; 2.40 A; A=153-451, P=53-152.
DR   PDB; 2W2N; X-ray; 2.30 A; A=153-451, P=53-152.
DR   PDB; 2W2O; X-ray; 2.62 A; A=153-451, P=53-152.
DR   PDB; 2W2P; X-ray; 2.62 A; A=153-451, P=53-152.
DR   PDB; 2W2Q; X-ray; 2.33 A; A=153-451, P=53-152.
DR   PDB; 2XTJ; X-ray; 2.70 A; A=153-451, P=53-152.
DR   PDB; 3BPS; X-ray; 2.41 A; A=153-692, P=53-152.
DR   PDB; 3GCW; X-ray; 2.70 A; A=153-692, P=53-152.
DR   PDB; 3GCX; X-ray; 2.70 A; A=153-692, P=53-152.
DR   PDB; 3H42; X-ray; 2.30 A; A=31-152, B=153-692.
DR   PDB; 3M0C; X-ray; 7.01 A; A=29-152, B=153-692.
DR   PDB; 3P5B; X-ray; 3.30 A; A=153-692, P=61-152.
DR   PDB; 3P5C; X-ray; 4.20 A; A=153-692, P=61-152.
DR   PDB; 3SQO; X-ray; 2.70 A; A=153-692, P=31-152.
DR   PDB; 4K8R; X-ray; 3.22 A; A=61-152, B=153-692.
DR   PDB; 4NE9; X-ray; 2.60 A; A/B=153-692, C/P=1-152.
DR   PDB; 4NMX; X-ray; 1.85 A; A=31-152, B=153-452.
DR   PDB; 4OV6; X-ray; 2.69 A; A/D=60-152, B/E=153-446.
DR   PDBsum; 2P4E; -.
DR   PDBsum; 2PMW; -.
DR   PDBsum; 2QTW; -.
DR   PDBsum; 2W2M; -.
DR   PDBsum; 2W2N; -.
DR   PDBsum; 2W2O; -.
DR   PDBsum; 2W2P; -.
DR   PDBsum; 2W2Q; -.
DR   PDBsum; 2XTJ; -.
DR   PDBsum; 3BPS; -.
DR   PDBsum; 3GCW; -.
DR   PDBsum; 3GCX; -.
DR   PDBsum; 3H42; -.
DR   PDBsum; 3M0C; -.
DR   PDBsum; 3P5B; -.
DR   PDBsum; 3P5C; -.
DR   PDBsum; 3SQO; -.
DR   PDBsum; 4K8R; -.
DR   PDBsum; 4NE9; -.
DR   PDBsum; 4NMX; -.
DR   PDBsum; 4OV6; -.
DR   ProteinModelPortal; Q8NBP7; -.
DR   SMR; Q8NBP7; 61-682.
DR   BioGrid; 129116; 25.
DR   DIP; DIP-29694N; -.
DR   IntAct; Q8NBP7; 3.
DR   MINT; MINT-3041747; -.
DR   STRING; 9606.ENSP00000303208; -.
DR   BindingDB; Q8NBP7; -.
DR   ChEMBL; CHEMBL2929; -.
DR   GuidetoPHARMACOLOGY; 2388; -.
DR   MEROPS; S08.039; -.
DR   PhosphoSite; Q8NBP7; -.
DR   BioMuta; PCSK9; -.
DR   DMDM; 317373487; -.
DR   MaxQB; Q8NBP7; -.
DR   PaxDb; Q8NBP7; -.
DR   PRIDE; Q8NBP7; -.
DR   DNASU; 255738; -.
DR   Ensembl; ENST00000302118; ENSP00000303208; ENSG00000169174.
DR   GeneID; 255738; -.
DR   KEGG; hsa:255738; -.
DR   UCSC; uc001cyf.2; human. [Q8NBP7-1]
DR   CTD; 255738; -.
DR   GeneCards; GC01P055505; -.
DR   GeneReviews; PCSK9; -.
DR   H-InvDB; HIX0023558; -.
DR   HGNC; HGNC:20001; PCSK9.
DR   HPA; CAB025575; -.
DR   MIM; 603776; phenotype.
DR   MIM; 607786; gene.
DR   neXtProt; NX_Q8NBP7; -.
DR   Orphanet; 426; Familial hypobetalipoproteinemia.
DR   Orphanet; 406; Heterozygous familial hypercholesterolemia.
DR   Orphanet; 391665; Homozygous familial hypercholesterolemia.
DR   PharmGKB; PA38617; -.
DR   eggNOG; COG1404; -.
DR   GeneTree; ENSGT00490000043472; -.
DR   HOGENOM; HOG000049267; -.
DR   HOVERGEN; HBG053530; -.
DR   InParanoid; Q8NBP7; -.
DR   KO; K13050; -.
DR   OMA; CHAPGLE; -.
DR   OrthoDB; EOG79PJNT; -.
DR   PhylomeDB; Q8NBP7; -.
DR   TreeFam; TF106271; -.
DR   BRENDA; 3.4.21.61; 2681.
DR   SignaLink; Q8NBP7; -.
DR   EvolutionaryTrace; Q8NBP7; -.
DR   GeneWiki; PCSK9; -.
DR   GenomeRNAi; 255738; -.
DR   NextBio; 92626; -.
DR   PRO; PR:Q8NBP7; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; Q8NBP7; -.
DR   CleanEx; HS_PCSK9; -.
DR   Genevisible; Q8NBP7; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0030134; C:ER to Golgi transport vesicle; IEA:Ensembl.
DR   GO; GO:0005615; C:extracellular space; IDA:HGNC.
DR   GO; GO:0031232; C:extrinsic component of external side of plasma membrane; IC:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005770; C:late endosome; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:1990667; C:PCSK9-AnxA2 complex; IDA:BHF-UCL.
DR   GO; GO:1990666; C:PCSK9-LDLR complex; IDA:BHF-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0034185; F:apolipoprotein binding; ISS:UniProtKB.
DR   GO; GO:0034190; F:apolipoprotein receptor binding; IDA:BHF-UCL.
DR   GO; GO:0030169; F:low-density lipoprotein particle binding; ISS:UniProtKB.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; IDA:HGNC.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0043621; F:protein self-association; IDA:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IPI:BHF-UCL.
DR   GO; GO:0030547; F:receptor inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IDA:HGNC.
DR   GO; GO:0019871; F:sodium channel inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0034189; F:very-low-density lipoprotein particle binding; ISS:UniProtKB.
DR   GO; GO:0070326; F:very-low-density lipoprotein particle receptor binding; IDA:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:HGNC.
DR   GO; GO:0009267; P:cellular response to starvation; ISS:HGNC.
DR   GO; GO:0042632; P:cholesterol homeostasis; IMP:HGNC.
DR   GO; GO:0008203; P:cholesterol metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0001822; P:kidney development; ISS:HGNC.
DR   GO; GO:0042157; P:lipoprotein metabolic process; IEA:Ensembl.
DR   GO; GO:0001889; P:liver development; ISS:HGNC.
DR   GO; GO:0032802; P:low-density lipoprotein particle receptor catabolic process; IDA:UniProtKB.
DR   GO; GO:0007041; P:lysosomal transport; IDA:BHF-UCL.
DR   GO; GO:0010989; P:negative regulation of low-density lipoprotein particle clearance; IDA:BHF-UCL.
DR   GO; GO:2000272; P:negative regulation of receptor activity; IDA:BHF-UCL.
DR   GO; GO:0001920; P:negative regulation of receptor recycling; IDA:BHF-UCL.
DR   GO; GO:2000650; P:negative regulation of sodium ion transmembrane transporter activity; IDA:BHF-UCL.
DR   GO; GO:0022008; P:neurogenesis; ISS:HGNC.
DR   GO; GO:0030182; P:neuron differentiation; ISS:HGNC.
DR   GO; GO:0006644; P:phospholipid metabolic process; IEA:Ensembl.
DR   GO; GO:0032805; P:positive regulation of low-density lipoprotein particle receptor catabolic process; IDA:BHF-UCL.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IMP:HGNC.
DR   GO; GO:0002092; P:positive regulation of receptor internalization; IDA:BHF-UCL.
DR   GO; GO:0016540; P:protein autoprocessing; IDA:HGNC.
DR   GO; GO:0043523; P:regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0010469; P:regulation of receptor activity; IDA:BHF-UCL.
DR   GO; GO:0006641; P:triglyceride metabolic process; IEA:Ensembl.
DR   Gene3D; 3.40.50.200; -; 1.
DR   InterPro; IPR000209; Peptidase_S8/S53_dom.
DR   InterPro; IPR015500; Peptidase_S8_subtilisin-rel.
DR   InterPro; IPR009020; Prot_inh_propept.
DR   InterPro; IPR010259; S8pro/Inhibitor_I9.
DR   PANTHER; PTHR10795; PTHR10795; 1.
DR   Pfam; PF05922; Inhibitor_I9; 1.
DR   Pfam; PF00082; Peptidase_S8; 1.
DR   PRINTS; PR00723; SUBTILISIN.
DR   SUPFAM; SSF52743; SSF52743; 1.
DR   SUPFAM; SSF54897; SSF54897; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Autocatalytic cleavage;
KW   Calcium; Cholesterol metabolism; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Endoplasmic reticulum; Endosome; Glycoprotein; Golgi apparatus;
KW   Hydrolase; Lipid metabolism; Lysosome; Phosphoprotein; Polymorphism;
KW   Protease; Reference proteome; Secreted; Serine protease; Signal;
KW   Steroid metabolism; Sterol metabolism; Sulfation; Zymogen.
FT   SIGNAL        1     30       {ECO:0000269|PubMed:12552133}.
FT   PROPEP       31    152       {ECO:0000269|PubMed:12552133}.
FT                                /FTId=PRO_0000027120.
FT   CHAIN       153    692       Proprotein convertase subtilisin/kexin
FT                                type 9.
FT                                /FTId=PRO_0000027121.
FT   DOMAIN      182    424       Peptidase S8.
FT   REGION      450    692       C-terminal domain.
FT   ACT_SITE    186    186       Charge relay system. {ECO:0000250}.
FT   ACT_SITE    226    226       Charge relay system. {ECO:0000250}.
FT   ACT_SITE    386    386       Charge relay system. {ECO:0000250}.
FT   SITE        152    153       Cleavage; by autolysis.
FT   SITE        218    219       Cleavage; by furin and PCSK5.
FT   MOD_RES      38     38       Sulfotyrosine.
FT                                {ECO:0000269|PubMed:16912035}.
FT   MOD_RES      47     47       Phosphoserine.
FT                                {ECO:0000269|PubMed:18498363}.
FT   MOD_RES     688    688       Phosphoserine.
FT                                {ECO:0000269|PubMed:17081983,
FT                                ECO:0000269|PubMed:18498363,
FT                                ECO:0000269|PubMed:20068231,
FT                                ECO:0000269|PubMed:21406692}.
FT   CARBOHYD    533    533       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16912035}.
FT   DISULFID    223    255       {ECO:0000255}.
FT   DISULFID    323    358       {ECO:0000255}.
FT   DISULFID    457    527       {ECO:0000255}.
FT   DISULFID    477    526       {ECO:0000255}.
FT   DISULFID    486    509       {ECO:0000255}.
FT   DISULFID    534    601       {ECO:0000255}.
FT   DISULFID    552    600       {ECO:0000255}.
FT   DISULFID    562    588       {ECO:0000255}.
FT   DISULFID    608    679       {ECO:0000255}.
FT   DISULFID    626    678       {ECO:0000255}.
FT   DISULFID    635    654       {ECO:0000255}.
FT   VAR_SEQ       1    174       MGTVSSRRSWWPLPLLLLLLLLLGPAGARAQEDEDGDYEEL
FT                                VLALRSEEDGLAEAPEHGTTATFHRCAKDPWRLPGTYVVVL
FT                                KEETHLSQSERTARRLQAQAARRGYLTKILHVFHGLLPGFL
FT                                VKMSGDLLELALKLPHVDYIEEDSSVFAQSIPWNLERITPP
FT                                RYRADEYQPP -> MSPWK (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_008844.
FT   VAR_SEQ     333    365       VITVGATNAQDQPVTLGTLGTNFGRCVDLFAPG -> GRTS
FT                                LVPPATAAPALCHRVGHHRLLPTWLALQP (in isoform
FT                                2). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_008845.
FT   VAR_SEQ     366    692       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_008846.
FT   VARIANT      23     23       L -> LL (this polymoprhism seems to have
FT                                a modifier effect on LDLR mutation and
FT                                familial hypercholesterolemia).
FT                                {ECO:0000269|PubMed:19319977,
FT                                ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|Ref.4, ECO:0000269|Ref.5}.
FT                                /FTId=VAR_021336.
FT   VARIANT      46     46       R -> L (polymorphism; associated with
FT                                lower plasma levels of low-density
FT                                lipoprotein cholesterol and reduced
FT                                phosphorylation at Ser-47;
FT                                dbSNP:rs11591147).
FT                                {ECO:0000269|PubMed:12730697,
FT                                ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_017197.
FT   VARIANT      53     53       A -> V (polymorphism; associated with
FT                                reduced phosphorylation at Ser-47;
FT                                dbSNP:rs11583680).
FT                                {ECO:0000269|PubMed:12730697,
FT                                ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_017198.
FT   VARIANT      57     57       E -> K. {ECO:0000269|PubMed:16465619}.
FT                                /FTId=VAR_025451.
FT   VARIANT      77     77       T -> I.
FT                                /FTId=VAR_058520.
FT   VARIANT      93     93       R -> C (in dbSNP:rs151193009).
FT                                /FTId=VAR_058521.
FT   VARIANT     106    106       G -> R.
FT                                /FTId=VAR_058522.
FT   VARIANT     114    114       V -> A.
FT                                /FTId=VAR_058523.
FT   VARIANT     127    127       S -> R (in HCHOLA3; dbSNP:rs28942111).
FT                                {ECO:0000269|PubMed:12730697}.
FT                                /FTId=VAR_017199.
FT   VARIANT     129    129       D -> G (in HCHOLA3).
FT                                /FTId=VAR_058524.
FT   VARIANT     157    157       N -> K.
FT                                /FTId=VAR_058525.
FT   VARIANT     174    174       P -> S (found in patients with familial
FT                                hypercholesterolemia carrying a
FT                                homozygous LDLR mutation; acts as a
FT                                disease modifier resulting in a mild
FT                                phenotype).
FT                                {ECO:0000269|PubMed:22417841}.
FT                                /FTId=VAR_067351.
FT   VARIANT     215    215       R -> H (in HCHOLA3).
FT                                /FTId=VAR_058526.
FT   VARIANT     216    216       F -> L (in HCHOLA3; partial loss of
FT                                cleavage by furin and PCSK5;
FT                                dbSNP:rs28942112).
FT                                {ECO:0000269|PubMed:12730697}.
FT                                /FTId=VAR_017200.
FT   VARIANT     218    218       R -> S (in HCHOLA3; complete loss of
FT                                cleavage by furin and PCSK5; reduces
FT                                glycosylation levels; no effect on
FT                                protein sulfation and phosphorylation; no
FT                                effect on protein sulfation but inhibits
FT                                phosphorylation when associated with Y-
FT                                374; highly reduces LDL uptake when
FT                                associated with Y-374).
FT                                {ECO:0000269|PubMed:18799458,
FT                                ECO:0000269|PubMed:24808179}.
FT                                /FTId=VAR_058527.
FT   VARIANT     219    219       Q -> E.
FT                                /FTId=VAR_058528.
FT   VARIANT     237    237       R -> W. {ECO:0000269|PubMed:16465619}.
FT                                /FTId=VAR_025452.
FT   VARIANT     239    239       A -> D.
FT                                /FTId=VAR_058529.
FT   VARIANT     253    253       L -> F (polymorphism; associated with
FT                                lower plasma levels of low-density
FT                                lipoprotein cholesterol;
FT                                dbSNP:rs28362270).
FT                                {ECO:0000269|PubMed:16465619}.
FT                                /FTId=VAR_025453.
FT   VARIANT     357    357       R -> H (in HCHOLA3).
FT                                /FTId=VAR_058530.
FT   VARIANT     374    374       D -> H (in HCHOLA3).
FT                                /FTId=VAR_058531.
FT   VARIANT     374    374       D -> Y (in HCHOLA3; partial loss of
FT                                cleavage by furin and PCSK5; no effect on
FT                                protein sulfation but inhibits
FT                                phosphorylation when associated with S-
FT                                218; highly increases LDL uptake when
FT                                associated with S-218).
FT                                {ECO:0000269|PubMed:18799458,
FT                                ECO:0000269|PubMed:24808179}.
FT                                /FTId=VAR_058532.
FT   VARIANT     391    391       H -> N. {ECO:0000269|PubMed:16465619}.
FT                                /FTId=VAR_025454.
FT   VARIANT     394    394       G -> S (found in a patient associated
FT                                with autosomal dominant
FT                                hypercholesterolemia; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:22095935}.
FT                                /FTId=VAR_067282.
FT   VARIANT     417    417       H -> Q (in dbSNP:rs143275858).
FT                                {ECO:0000269|PubMed:16465619}.
FT                                /FTId=VAR_025455.
FT   VARIANT     425    425       N -> S (in dbSNP:rs28362261).
FT                                {ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021337.
FT   VARIANT     443    443       A -> T (polymorphism; associated with
FT                                lower plasma levels of low-density
FT                                lipoprotein cholesterol; more extensive
FT                                cleavage by furin and PCSK5;
FT                                dbSNP:rs28362263).
FT                                {ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021338.
FT   VARIANT     452    452       G -> D.
FT                                /FTId=VAR_058533.
FT   VARIANT     469    469       R -> W (in dbSNP:rs141502002).
FT                                {ECO:0000269|PubMed:16465619}.
FT                                /FTId=VAR_025456.
FT   VARIANT     474    474       V -> I (in dbSNP:rs562556).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|PubMed:17971861,
FT                                ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|Ref.1, ECO:0000269|Ref.4,
FT                                ECO:0000269|Ref.5, ECO:0000269|Ref.7}.
FT                                /FTId=VAR_021339.
FT   VARIANT     482    482       E -> G. {ECO:0000269|PubMed:16465619}.
FT                                /FTId=VAR_025457.
FT   VARIANT     482    482       E -> Q (no effect on interaction with
FT                                ANXA2). {ECO:0000269|PubMed:24808179}.
FT                                /FTId=VAR_073657.
FT   VARIANT     496    496       R -> W (in HCHOLA3).
FT                                /FTId=VAR_058534.
FT   VARIANT     515    515       F -> L. {ECO:0000269|PubMed:16465619}.
FT                                /FTId=VAR_025458.
FT   VARIANT     522    522       A -> T.
FT                                /FTId=VAR_058535.
FT   VARIANT     553    553       H -> R (in dbSNP:rs28362270).
FT                                {ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021340.
FT   VARIANT     554    554       Q -> E (increases interaction with ANXA2;
FT                                dbSNP:rs149311926).
FT                                {ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|PubMed:18799458}.
FT                                /FTId=VAR_025459.
FT   VARIANT     616    616       P -> L.
FT                                /FTId=VAR_058536.
FT   VARIANT     619    619       Q -> P (in dbSNP:rs28362277).
FT                                {ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021341.
FT   VARIANT     668    668       S -> R.
FT                                /FTId=VAR_058537.
FT   VARIANT     670    670       G -> E (in dbSNP:rs505151).
FT                                {ECO:0000269|PubMed:12730697,
FT                                ECO:0000269|PubMed:16465619,
FT                                ECO:0000269|PubMed:17971861,
FT                                ECO:0000269|PubMed:22095935,
FT                                ECO:0000269|Ref.1, ECO:0000269|Ref.4,
FT                                ECO:0000269|Ref.5, ECO:0000269|Ref.7}.
FT                                /FTId=VAR_017201.
FT   MUTAGEN      67     67       C->A: Does not affect multimerization or
FT                                zymogen processing.
FT                                {ECO:0000269|PubMed:12552133}.
FT   MUTAGEN     226    226       H->A: Remains in the endoplasmic
FT                                reticulum and is not secreted.
FT                                {ECO:0000269|PubMed:12552133}.
FT   MUTAGEN     533    533       N->A: 1.5 kDa decrease of the apparent
FT                                molecular mass of pro-PCSK9 and PCSK9 and
FT                                no effect on processing and secretion.
FT                                {ECO:0000269|PubMed:12552133}.
FT   CONFLICT    423    423       V -> A (in Ref. 3; BAC11572).
FT                                {ECO:0000305}.
FT   STRAND       63     65       {ECO:0000244|PDB:4NMX}.
FT   HELIX        70     72       {ECO:0000244|PDB:4NMX}.
FT   STRAND       73     82       {ECO:0000244|PDB:4NMX}.
FT   STRAND       84     86       {ECO:0000244|PDB:4OV6}.
FT   HELIX        88    104       {ECO:0000244|PDB:4NMX}.
FT   STRAND      110    115       {ECO:0000244|PDB:4NMX}.
FT   STRAND      117    119       {ECO:0000244|PDB:4NMX}.
FT   STRAND      121    125       {ECO:0000244|PDB:4NMX}.
FT   HELIX       128    130       {ECO:0000244|PDB:4NMX}.
FT   HELIX       131    135       {ECO:0000244|PDB:4NMX}.
FT   STRAND      140    151       {ECO:0000244|PDB:4NMX}.
FT   HELIX       156    160       {ECO:0000244|PDB:4NMX}.
FT   HELIX       168    170       {ECO:0000244|PDB:3BPS}.
FT   STRAND      181    187       {ECO:0000244|PDB:4NMX}.
FT   TURN        194    199       {ECO:0000244|PDB:4NMX}.
FT   STRAND      200    206       {ECO:0000244|PDB:4NMX}.
FT   STRAND      212    214       {ECO:0000244|PDB:4NMX}.
FT   TURN        218    220       {ECO:0000244|PDB:3H42}.
FT   TURN        221    224       {ECO:0000244|PDB:2QTW}.
FT   HELIX       225    235       {ECO:0000244|PDB:4NMX}.
FT   TURN        237    239       {ECO:0000244|PDB:4NMX}.
FT   STRAND      241    244       {ECO:0000244|PDB:2P4E}.
FT   STRAND      246    251       {ECO:0000244|PDB:4NMX}.
FT   STRAND      257    260       {ECO:0000244|PDB:4NMX}.
FT   HELIX       261    277       {ECO:0000244|PDB:4NMX}.
FT   STRAND      283    287       {ECO:0000244|PDB:4NMX}.
FT   STRAND      289    292       {ECO:0000244|PDB:4NMX}.
FT   HELIX       295    306       {ECO:0000244|PDB:4NMX}.
FT   STRAND      310    314       {ECO:0000244|PDB:4NMX}.
FT   STRAND      317    321       {ECO:0000244|PDB:4NMX}.
FT   HELIX       322    324       {ECO:0000244|PDB:4NMX}.
FT   TURN        327    329       {ECO:0000244|PDB:4NMX}.
FT   STRAND      333    339       {ECO:0000244|PDB:4NMX}.
FT   STRAND      343    345       {ECO:0000244|PDB:2PMW}.
FT   STRAND      349    352       {ECO:0000244|PDB:2W2Q}.
FT   STRAND      355    358       {ECO:0000244|PDB:3P5B}.
FT   STRAND      361    364       {ECO:0000244|PDB:4NMX}.
FT   STRAND      366    372       {ECO:0000244|PDB:4NMX}.
FT   STRAND      373    375       {ECO:0000244|PDB:2XTJ}.
FT   STRAND      378    382       {ECO:0000244|PDB:4NMX}.
FT   HELIX       385    402       {ECO:0000244|PDB:4NMX}.
FT   HELIX       408    417       {ECO:0000244|PDB:4NMX}.
FT   STRAND      419    422       {ECO:0000244|PDB:4NMX}.
FT   HELIX       426    428       {ECO:0000244|PDB:4NMX}.
FT   HELIX       431    433       {ECO:0000244|PDB:4NMX}.
FT   TURN        434    436       {ECO:0000244|PDB:4NMX}.
FT   STRAND      440    442       {ECO:0000244|PDB:3P5B}.
FT   STRAND      456    461       {ECO:0000244|PDB:2QTW}.
FT   STRAND      467    470       {ECO:0000244|PDB:3SQO}.
FT   STRAND      472    475       {ECO:0000244|PDB:2QTW}.
FT   STRAND      482    489       {ECO:0000244|PDB:2QTW}.
FT   STRAND      491    493       {ECO:0000244|PDB:3GCX}.
FT   STRAND      495    503       {ECO:0000244|PDB:2QTW}.
FT   STRAND      506    513       {ECO:0000244|PDB:2QTW}.
FT   STRAND      521    528       {ECO:0000244|PDB:2QTW}.
FT   STRAND      533    539       {ECO:0000244|PDB:2QTW}.
FT   STRAND      544    546       {ECO:0000244|PDB:2QTW}.
FT   STRAND      548    551       {ECO:0000244|PDB:2QTW}.
FT   STRAND      558    565       {ECO:0000244|PDB:2QTW}.
FT   STRAND      568    570       {ECO:0000244|PDB:2P4E}.
FT   STRAND      587    590       {ECO:0000244|PDB:2QTW}.
FT   STRAND      594    602       {ECO:0000244|PDB:2QTW}.
FT   STRAND      606    615       {ECO:0000244|PDB:2QTW}.
FT   STRAND      621    625       {ECO:0000244|PDB:2QTW}.
FT   STRAND      631    637       {ECO:0000244|PDB:2QTW}.
FT   STRAND      644    650       {ECO:0000244|PDB:2QTW}.
FT   STRAND      653    658       {ECO:0000244|PDB:2QTW}.
FT   STRAND      672    681       {ECO:0000244|PDB:2QTW}.
SQ   SEQUENCE   692 AA;  74286 MW;  9BCB9418B90AEE23 CRC64;
     MGTVSSRRSW WPLPLLLLLL LLLGPAGARA QEDEDGDYEE LVLALRSEED GLAEAPEHGT
     TATFHRCAKD PWRLPGTYVV VLKEETHLSQ SERTARRLQA QAARRGYLTK ILHVFHGLLP
     GFLVKMSGDL LELALKLPHV DYIEEDSSVF AQSIPWNLER ITPPRYRADE YQPPDGGSLV
     EVYLLDTSIQ SDHREIEGRV MVTDFENVPE EDGTRFHRQA SKCDSHGTHL AGVVSGRDAG
     VAKGASMRSL RVLNCQGKGT VSGTLIGLEF IRKSQLVQPV GPLVVLLPLA GGYSRVLNAA
     CQRLARAGVV LVTAAGNFRD DACLYSPASA PEVITVGATN AQDQPVTLGT LGTNFGRCVD
     LFAPGEDIIG ASSDCSTCFV SQSGTSQAAA HVAGIAAMML SAEPELTLAE LRQRLIHFSA
     KDVINEAWFP EDQRVLTPNL VAALPPSTHG AGWQLFCRTV WSAHSGPTRM ATAVARCAPD
     EELLSCSSFS RSGKRRGERM EAQGGKLVCR AHNAFGGEGV YAIARCCLLP QANCSVHTAP
     PAEASMGTRV HCHQQGHVLT GCSSHWEVED LGTHKPPVLR PRGQPNQCVG HREASIHASC
     CHAPGLECKV KEHGIPAPQE QVTVACEEGW TLTGCSALPG TSHVLGAYAV DNTCVVRSRD
     VSTTGSTSEG AVTAVAICCR SRHLAQASQE LQ
//
